91例骨肽注射液的不良反应报告分析  

Analysis of 91Cases of Adverse Drug Reactions of Ossotide Injection

作　　者：韩丹[1] 邵尉[1] 代菲[1] 储文功[1] 

机构地区：[1]第二军医大学药事管理教研室,上海200433

出　　处：《中国药事》2014年第4期444-446,共3页Chinese Pharmaceutical Affairs

摘　　要：目的探讨骨肽注射液不良反应发生的特点及相关因素,为临床安全用药提供参考。方法收集上海市药品不良反应监测中心2004~2011年自发呈报系统上报的91例骨肽注射液的不良反应（ADR）报告,对药物不良反应所涉及的患者年龄、性别,ADR类型、转归、临床表现等进行统计分析。结果91例报告中,男66例,女25例,〉40岁患者居多（占68.13%）;临床表现以皮肤及附件损害为主（占37.34%）,其次为胃肠系统损害（占24.68%）。结论临床应重视对老年患者、过敏体质患者骨肽注射液的药物不良反应监测,有痛风病史患者宜慎用骨肽注射液。Objective To study the characteristics of adverse drug reactions （ADRs） caused by Ossotide Injection and to provide some rational clinical guidance. Methods A total of 91 reports of adverse reactions caused by Ossotide Injection were collected from January 2004 to December 2011 and statistically analyzed in respects of patients＇gender and age, involved types, outcomes, clinical manifestations, etc. Results Of the 91 cases, there were 66 males and 25 females, 68.13% were adults over the age of 40. Skin and appendage damage was the dominant clinical manifestation in ADR cases （37.34%）, followd by gastrointestinal damage （24.68%）. Conclusion Clinical attention should be paid to the ADRs induced by Ossotide Injection in gerontal patients and patients with, allergic constitution, therefore, patients with history of gout should use it with caution.

关 键 词：骨肽注射液 药品不良反应 合理用药 

分 类 号：R994.11[医药卫生—毒理学]